{"transactions":[{"id":774971,"issuer":{"id":690,"kind":"organization","name":"Lantheus Holdings, Inc.","symbol":"LNTH"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2026-05-18T16:34:22.000Z","date":"2026-05-14","kind":"grant","planned":false,"acquired":true,"shares":4137,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":8019,"source":{"system":"sec-edgar","filing":"0002064832-26-000203","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000206483226000203/form4.xml","form_type":"4"}},{"id":912075,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-02-11T02:09:41.000Z","date":"2026-02-09","kind":"sale","planned":false,"acquired":false,"shares":889,"price":2.3929,"value":2127.2881,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":79133,"source":{"system":"sec-edgar","filing":"0001500189-26-000004","document":"wk-form4_1770775778.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000150018926000004/wk-form4_1770775778.xml","form_type":"4"}},{"id":912074,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2026-02-11T02:09:41.000Z","date":"2026-02-06","kind":"sale","planned":false,"acquired":false,"shares":7866,"price":2.4297,"value":19112.0202,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units previously granted to the Reporting Person."}],"balance_after":80022,"source":{"system":"sec-edgar","filing":"0001500189-26-000004","document":"wk-form4_1770775778.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000150018926000004/wk-form4_1770775778.xml","form_type":"4"}},{"id":942147,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-01-10T01:33:08.000Z","date":"2026-01-08","kind":"grant","planned":false,"acquired":true,"shares":775000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":775000,"derivative":{"exercise_price":2.84,"expiration_date":"2036-01-07","underlying":"Common Stock","underlying_shares":775000},"source":{"system":"sec-edgar","filing":"0001500189-26-000002","document":"wk-form4_1768008785.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000150018926000002/wk-form4_1768008785.xml","form_type":"4"}},{"id":1145344,"issuer":{"id":690,"kind":"organization","name":"Lantheus Holdings, Inc.","symbol":"LNTH"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2025-05-16T16:39:10.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":4543,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":4543,"derivative":{"exercise_price":78.81,"exercise_date":"2026-05-14","expiration_date":"2035-05-14","underlying":"Common Stock","underlying_shares":4543},"source":{"system":"sec-edgar","filing":"0001062993-25-009692","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000106299325009692/form4.xml","form_type":"4"}},{"id":1145343,"issuer":{"id":690,"kind":"organization","name":"Lantheus Holdings, Inc.","symbol":"LNTH"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-05-16T16:39:10.000Z","date":"2025-05-14","kind":"grant","planned":false,"acquired":true,"shares":2537,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":3882,"source":{"system":"sec-edgar","filing":"0001062993-25-009692","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000106299325009692/form4.xml","form_type":"4"}},{"id":1281928,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-05T23:29:57.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":59388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The options will vest over four years in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":59388,"derivative":{"exercise_price":1.68,"expiration_date":"2035-02-02","underlying":"Common Stock","underlying_shares":59388},"source":{"system":"sec-edgar","filing":"0001725160-25-000036","document":"wk-form4_1738798191.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000036/wk-form4_1738798191.xml","form_type":"4"}},{"id":1281927,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-02-05T23:29:57.000Z","date":"2025-02-03","kind":"grant","planned":false,"acquired":true,"shares":59388,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a two year period following the grant date, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":87888,"source":{"system":"sec-edgar","filing":"0001725160-25-000036","document":"wk-form4_1738798191.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000036/wk-form4_1738798191.xml","form_type":"4"}},{"id":1284939,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Common Stock","published_at":"2025-02-04T21:37:15.000Z","date":"2025-01-31","kind":"purchase","planned":false,"acquired":true,"shares":28500,"price":1.7314,"value":49344.9,"ownership":{"direct":true},"balance_after":28500,"source":{"system":"sec-edgar","filing":"0001725160-25-000028","document":"wk-form4_1738705022.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516025000028/wk-form4_1738705022.xml","form_type":"4"}},{"id":1345121,"issuer":{"id":5772,"kind":"organization","name":"Zentalis Pharmaceuticals, Inc."},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO & President"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-12-04T00:02:15.000Z","date":"2024-12-02","kind":"grant","planned":false,"acquired":true,"shares":3028800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The options will vest over a four-year period following the vesting commencement date of November 13, 2024, in substantially equal monthly installments until the options are fully vested, subject to the Reporting Person's continued service with the Issuer."}],"balance_after":3028800,"derivative":{"exercise_price":3.66,"expiration_date":"2034-12-02","underlying":"Common Stock","underlying_shares":3028800},"source":{"system":"sec-edgar","filing":"0001725160-24-000189","document":"wk-form4_1733270528.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1725160/000172516024000189/wk-form4_1733270528.xml","form_type":"4"}},{"id":1408585,"issuer":{"id":690,"kind":"organization","name":"Lantheus Holdings, Inc.","symbol":"LNTH"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2024-09-12T17:57:56.000Z","date":"2024-09-10","kind":"grant","planned":false,"acquired":true,"shares":2506,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":2506,"derivative":{"exercise_price":99.08,"exercise_date":"2025-09-10","expiration_date":"2034-09-10","underlying":"Common Stock","underlying_shares":2506},"source":{"system":"sec-edgar","filing":"0001062993-24-016538","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000106299324016538/form4.xml","form_type":"4"}},{"id":1408584,"issuer":{"id":690,"kind":"organization","name":"Lantheus Holdings, Inc.","symbol":"LNTH"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-09-12T17:57:56.000Z","date":"2024-09-10","kind":"grant","planned":false,"acquired":true,"shares":1345,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":1345,"source":{"system":"sec-edgar","filing":"0001062993-24-016538","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000106299324016538/form4.xml","form_type":"4"}},{"id":1500889,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-28T20:30:49.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date."}],"balance_after":22500,"derivative":{"exercise_price":11.85,"expiration_date":"2031-05-22","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-24-065588","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000095017024065588/ownership.xml","form_type":"4"}},{"id":1500888,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-05-28T20:30:49.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":5357,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company."}],"balance_after":16071,"source":{"system":"sec-edgar","filing":"0000950170-24-065588","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000095017024065588/ownership.xml","form_type":"4"}},{"id":1584066,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-03-11T17:17:04.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":40759,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":8.9,"underlying":"Common Stock","underlying_shares":40759},"source":{"system":"sec-edgar","filing":"0000950170-24-029430","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000095017024029430/ownership.xml","form_type":"4"}},{"id":1584065,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2024-03-11T17:17:04.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":2765,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"(Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F7","text":"Pursuant to the terms of the Merger Agreement, immediately prior to the Effective Time, each outstanding option to purchase shares of Common Stock granted under an Issuer equity plan (each, a \"Stock Option\"), to the extent unvested, became fully vested and exercisable effective immediately prior to, and contingent upon, the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, (i) each Stock Option that was outstanding and unexercised immediately prior to the Effective Time and that had a per share exercise price that is less than the Common Stock Merger Consideration (each, an \"In the Money Option\") was cancelled in exchange for the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (1) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time and (2) the excess of the"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"(Continued from footnote 7) Common Stock Merger Consideration over the per share exercise price payable for such Stock Option immediately prior to the Effective Time and (ii) each Stock Option other than an In the Money Option then outstanding and unexercised was cancelled with no consideration payable in respect thereof."}],"balance_after":0,"derivative":{"exercise_price":21.1453,"underlying":"Common Stock","underlying_shares":2765},"source":{"system":"sec-edgar","filing":"0000950170-24-029430","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000095017024029430/ownership.xml","form_type":"4"}},{"id":1584064,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-11T17:17:04.000Z","date":"2024-03-11","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":269381,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F4","text":"Includes 259,750 RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the \"Effective Time\"), each outstanding RSU was cancelled and automatically converted into the right to receive an amount in cash (without interest and subject to any applicable withholding or other taxes) equal to the product of (i) the Common Stock Merger Consideration (as defined below) payable with respect to such RSU multiplied by (ii) the total number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, with the number of shares of Company Common Stock subject to any such Company RSU that vests based on the achievement of performance goals determined in accordance with the applicable award agreement."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding share of Common Stock was cancelled and automatically converted into the right to receive $23.00 in cash, without interest (the \"Common Stock Merger Consideration\")."},{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F3","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of January 7, 2024, by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company (\"Parent\"), and Hawaii Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub merged with and into the Issuer on March 11, 2024, with the Issuer surviving the merger as a wholly owned subsidiary of Parent (the \"Merger\")."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000950170-24-029430","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000095017024029430/ownership.xml","form_type":"4"}},{"id":1584063,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-03-11T17:17:04.000Z","date":"2024-03-11","kind":"grant","planned":false,"acquired":true,"shares":31250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Reflects the number of restricted stock units (\"RSUs\") vested upon the achievement of certain performance-related metrics. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.0001 per share (\"Common Stock\"), issuable upon the vesting of RSUs."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 6,128 shares of Common Stock acquired under the Issuer's employee stock purchase plan on February 29, 2024."}],"balance_after":269381,"source":{"system":"sec-edgar","filing":"0000950170-24-029430","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000095017024029430/ownership.xml","form_type":"4"}},{"id":1682678,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2024-01-09T16:30:07.000Z","date":"2024-01-07","kind":"grant","planned":false,"acquired":true,"shares":178500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"The grant of restricted stock units (\"RSUs\") to the Reporting Person as reported herein was approved by the Issuer's Compensation Committee on January 7, 2024 (\"Grant Date\") as part of the Issuer's annual grant of equity awards in the ordinary course. Each RSU represents a contingent right to receive one share of the Issuer's common stock, issuable upon the vesting and settlement of RSUs."},{"field":"shares","element":"transactionShares","label":"F2","text":"The RSUs vest quarterly over four years from the Grant Date, subject to acceleration and vesting in full upon a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan) of the Issuer, and subject to the continuing service of the Reporting Person on each vesting date."}],"balance_after":232003,"source":{"system":"sec-edgar","filing":"0000950170-24-003365","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000095017024003365/ownership.xml","form_type":"4"}},{"id":1728563,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Common Stock","published_at":"2023-11-28T16:30:30.000Z","date":"2023-11-26","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive one share of the Issuer's common stock, issuable upon the vesting and settlement of RSUs."},{"field":"shares","element":"transactionShares","label":"F2","text":"25% of the RSUs will vest on each May 26th and November 26th of 2024 and 2025, subject to acceleration and vesting in full upon a Change in Control (as defined in the Issuer's 2019 Equity Incentive Plan) of the Issuer, and subject to the continuing employment of the Reporting Person on each vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 500 shares acquired under the Issuer's employee stock purchase plan on September 30, 2022, 750 shares acquired on March 31, 2023, and 2,253 shares acquired on September 29, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F4","text":"Shares reflect 1:10 reverse stock split effective September 1, 2023."}],"balance_after":53503,"source":{"system":"sec-edgar","filing":"0001209191-23-056805","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919123056805/doc4.xml","form_type":"4"}},{"id":1873672,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-31T17:23:48.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date."}],"balance_after":22500,"derivative":{"exercise_price":11.2,"expiration_date":"2030-05-25","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-23-033162","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919123033162/doc4.xml","form_type":"4"}},{"id":1873671,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-05-31T17:23:48.000Z","date":"2023-05-26","kind":"grant","planned":false,"acquired":true,"shares":5357,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"These securities are restricted stock units (\"RSUs\"). Each RSU represents a contingent right to receive one share of DVAX Common Stock. The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred six months and one day after the Reporting Person no longer provides services to the Company. The reporting person has reported prior awards of restricted stock units in Table II on Form 4. The total reported in Column 5 includes 5,357 newly awarded restricted stock units and 5,357 restricted stock units previously reported in Table II."}],"balance_after":10714,"source":{"system":"sec-edgar","filing":"0001209191-23-033162","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919123033162/doc4.xml","form_type":"4"}},{"id":1937866,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2023-03-27T19:57:01.000Z","date":"2023-03-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1429,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the \"Merger Agreement\"), by and among CalciMedica, Inc. (\"Private CalciMedica\"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the \"Merger\"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Julia Eastland's options and restricted stock units (\"RSUs\") were fully accelerated and the RSUs were settled on March 23, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the \"Merger Agreement\"), by and among CalciMedica, Inc. (\"Private CalciMedica\"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the \"Merger\"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Julia Eastland's options and restricted stock units (\"RSUs\") were fully accelerated and the RSUs were settled on March 23, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the \"Merger Agreement\"), by and among CalciMedica, Inc. (\"Private CalciMedica\"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the \"Merger\"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Julia Eastland's options and restricted stock units (\"RSUs\") were fully accelerated and the RSUs were settled on March 23, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the \"Merger Agreement\"), by and among CalciMedica, Inc. (\"Private CalciMedica\"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the \"Merger\"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Julia Eastland's options and restricted stock units (\"RSUs\") were fully accelerated and the RSUs were settled on March 23, 2023."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1429},"source":{"system":"sec-edgar","filing":"0001209191-23-021301","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919123021301/doc4.xml","form_type":"4"}},{"id":1937865,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-03-27T19:57:01.000Z","date":"2023-03-23","kind":"disposition_to_issuer","planned":false,"acquired":true,"shares":1429,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Reflects a 14-to-1 reverse stock split effective March 17, 2023. Under the terms of the Agreement and Plan of Merger and Reorganization, dated as of November 21, 2022, as amended (the \"Merger Agreement\"), by and among CalciMedica, Inc. (\"Private CalciMedica\"), the Issuer and Camaro Merger Sub, Inc., a wholly-owned subsidiary of the Issuer (\"Merger Sub\"), on March 20, 2023, Merger Sub merged with and into Private CalciMedica (the \"Merger\"), with Private CalciMedica surviving the Merger as a wholly-owned subsidiary of the Issuer. Upon the closing of the Merger, each share of CalciMedica common capital stock was converted into the right to receive 0.0288 of a share of the Issuer's common stock. Subsequent to the Merger, the name of the Issuer was changed from Graybug Vision, Inc. to CalciMedica, Inc. In connection with the Merger, the vesting of Julia Eastland's options and restricted stock units (\"RSUs\") were fully accelerated and the RSUs were settled on March 23, 2023."}],"balance_after":1429,"source":{"system":"sec-edgar","filing":"0001209191-23-021301","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919123021301/doc4.xml","form_type":"4"}},{"id":2044969,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2023-01-26T16:05:00.000Z","date":"2023-01-24","kind":"grant","acquired":true,"shares":407600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1/48th of 203,800 stock option, representing one-half of the total option grant, will vest and become exercisable monthly on the same day of each month following the vesting commencement date of January 24, 2023 (the \"VCD\"), and 25% of 203,800 stock option, representing the second one-half of the total option grant, will vest and become exercisable every six months following the VCD, all subject to the continuing employment of the Reporting Person on each vesting date."}],"balance_after":407600,"derivative":{"exercise_price":0.89,"expiration_date":"2033-01-23","underlying":"Common Stock","underlying_shares":407600},"source":{"system":"sec-edgar","filing":"0001209191-23-005030","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919123005030/doc4.xml","form_type":"4"}},{"id":2244631,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-06-03T17:35:05.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each restricted stock unit represents a contingent right to receive one share of the issuer's Common Stock, subject to the reporting person's continued status as a service provider to the issuer."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The award vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of\nits stockholders, subject to the reporting person's continuous service to the issuer on such date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These restricted stock units do not expire; they either vest or are cancelled prior to the vesting date."}],"balance_after":20000,"derivative":{"underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-034256","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919122034256/doc4.xml","form_type":"4"}},{"id":2244630,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-06-03T17:35:05.000Z","date":"2022-06-02","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The award vests in full on the earlier of: (i) the one year anniversary of the grant date or (ii) the date of the issuer's 2023 Annual Meeting of\nits stockholders, subject to the reporting person's continuous service to the issuer on such date."}],"balance_after":20000,"derivative":{"exercise_price":0.984,"expiration_date":"2032-06-01","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-22-034256","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919122034256/doc4.xml","form_type":"4"}},{"id":2254037,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2022-05-27T17:01:34.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":22500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option grant fully vests and becomes exercisable one year from date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date."}],"balance_after":22500,"derivative":{"exercise_price":11.68,"expiration_date":"2029-05-25","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001209191-22-032616","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919122032616/doc4.xml","form_type":"4"}},{"id":2254036,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-05-27T17:01:34.000Z","date":"2022-05-26","kind":"grant","acquired":true,"shares":5357,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock.  The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock.  The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock.  The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each Restricted Stock Unit (\"RSU\") represents a contingent right to receive one share of common stock.  The RSU will fully vest one year from the date of grant, provided that Reporting Person continues to provide services to the Company through such vesting date. The release of RSU shares shall be mandatorily deferred until the Reporting Person no longer provides services to the Company."}],"balance_after":5357,"derivative":{"underlying":"Common Stock","underlying_shares":5357},"source":{"system":"sec-edgar","filing":"0001209191-22-032616","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919122032616/doc4.xml","form_type":"4"}},{"id":2519591,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President and CEO"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-11-09T16:02:22.000Z","date":"2021-11-08","kind":"grant","acquired":true,"shares":350000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Twenty-five percent of the stock option shall be fully vested and exercisable on the first anniversary of the vesting commencement date, November 8, 2022, and the remaining seventy-five percent shall vest over the following three years in equal monthly installments."}],"balance_after":350000,"derivative":{"exercise_price":6.85,"expiration_date":"2031-11-08","underlying":"Common Stock","underlying_shares":350000},"source":{"system":"sec-edgar","filing":"0001209191-21-063586","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919121063586/doc4.xml","form_type":"4"}},{"id":2680913,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2021-06-04T18:36:12.000Z","date":"2021-06-02","kind":"grant","acquired":true,"shares":12500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option award will fully vest upon the earlier of 1) the Issuer's next annual stockholder meeting, or 2) June 2, 2022, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":12500,"derivative":{"exercise_price":4.07,"expiration_date":"2031-06-01","underlying":"Common Stock","underlying_shares":12500},"source":{"system":"sec-edgar","filing":"0001209191-21-038388","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919121038388/doc4.xml","form_type":"4"}},{"id":2687291,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option (Right to Buy)","published_at":"2021-06-02T19:04:51.000Z","date":"2021-05-28","kind":"grant","acquired":true,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option vests fully on May 28, 2022, on the one year anniversary of the grant date."}],"balance_after":25000,"derivative":{"exercise_price":8.2,"expiration_date":"2028-05-27","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-21-037419","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919121037419/doc4.xml","form_type":"4"}},{"id":2712286,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-05-14T20:02:37.000Z","date":"2021-05-04","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"This option was erroneously reported with a price of $22.50 on the original Form 4 filed on May 7, 2021 due to an administrative error."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option will fully vest and become exercisable on May 3, 2022, subject to the continuous service of the Reporting Person with the Issuer on such date. The original Form 4 filed on May 7, 2021 erroneously reported this vesting date as May 4, 2022."}],"balance_after":10167,"derivative":{"exercise_price":23.2,"expiration_date":"2031-05-03","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-21-032956","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919121032956/doc4a.xml","form_type":"4/A","original_submission_date":"2021-05-07"}},{"id":2723126,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2021-05-07T21:55:18.000Z","date":"2021-05-04","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on May 4, 2022, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":10167,"derivative":{"exercise_price":22.5,"expiration_date":"2031-05-03","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-21-031106","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919121031106/doc4.xml","form_type":"4"}},{"id":3021686,"issuer":{"id":7804,"kind":"organization","name":"CalciMedica, Inc.","symbol":"CALC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-09-28T17:40:47.000Z","date":"2020-09-24","kind":"grant","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest as to 1/36th of the total shares on October 24, 2020 and on each monthly anniversary thereafter such that the option shall be fully vested on September 24, 2023, subject to the continued service of the Reporting Person to the Issuer through each vesting date."}],"balance_after":25000,"derivative":{"exercise_price":16,"expiration_date":"2030-09-23","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-20-052242","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919120052242/doc4.xml","form_type":"4"}},{"id":3079085,"issuer":{"id":66930,"kind":"organization","name":"DYNAVAX TECHNOLOGIES CORP","symbol":"DVAX"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2020-07-21T19:37:26.000Z","date":"2020-07-17","kind":"grant","acquired":true,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Not applicable."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option grant will vest over three years in equal installments on the anniversary of the grant date."}],"balance_after":50000,"derivative":{"exercise_price":11.37,"expiration_date":"2027-07-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-20-043248","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1029142/000120919120043248/doc4.xml","form_type":"4"}},{"id":3129059,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2020-06-01T21:47:42.000Z","date":"2020-05-28","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on May 28, 2021, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":10167,"derivative":{"exercise_price":20.59,"expiration_date":"2030-05-27","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-20-033322","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919120033322/doc4.xml","form_type":"4"}},{"id":3500525,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2019-06-05T17:22:02.000Z","date":"2019-06-03","kind":"grant","acquired":true,"shares":10167,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option will fully vest and become exercisable on June 3, 2020, subject to the continuous service of the Reporting Person with the Issuer on such date."}],"balance_after":10167,"derivative":{"exercise_price":11.84,"expiration_date":"2029-06-02","underlying":"Common Stock","underlying_shares":10167},"source":{"system":"sec-edgar","filing":"0001209191-19-034842","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919119034842/doc4.xml","form_type":"4"}},{"id":3574021,"issuer":{"id":11424,"kind":"organization","name":"Harpoon Therapeutics, Inc.","symbol":"HARP"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2019-03-29T16:21:02.000Z","date":"2019-02-07","kind":"grant","acquired":true,"shares":5907,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests and becomes exercisable as to 25% of the shares subject to the option on the last day of each calendar quarter following the grant date of February 7, 2019 (on March 31, 2019, June 30, 2019, September 30, 2019, and December 31, 2019), subject to the continuous service of the Reporting Person on each vesting date."}],"balance_after":5907,"derivative":{"exercise_price":14,"expiration_date":"2029-02-06","underlying":"Common Stock","underlying_shares":5907},"source":{"system":"sec-edgar","filing":"0001209191-19-021736","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919119021736/doc4.xml","form_type":"4"}},{"id":3998390,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Restricted Stock Units","published_at":"2018-03-13T18:01:16.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":199000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F21","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $1,990,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F21","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $1,990,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F22","text":"The restricted stock units were granted on January 31, 2018 and 25% of the shares vest on each anniversary of the grant date for four years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F18","text":"The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":199000},"source":{"system":"sec-edgar","filing":"0000899243-18-007292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":14,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000089924318007292/doc4.xml","form_type":"4"}},{"id":3998389,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Restricted Stock Units","published_at":"2018-03-13T18:01:16.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":16500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F19","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $165,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F19","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $165,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F20","text":"The restricted stock units were granted on September 18, 2017 and 25% of the shares vest on each anniversary of the grant date for four years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F18","text":"The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0000899243-18-007292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000089924318007292/doc4.xml","form_type":"4"}},{"id":3998388,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Restricted Stock Units","published_at":"2018-03-13T18:01:16.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":11300,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F16","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $113,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price."},{"field":"price","element":"transactionPricePerShare","label":"F16","text":"Pursuant to the Merger Agreement, the restricted stock units were cancelled in exchange for a cash payment of $113,000.00, which is the product of the total number of shares subject to such restricted stock unit grant multiplied by the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F17","text":"The restricted stock units were granted on January 11, 2017 and 25% of the shares vest on each anniversary of the grant date for four years."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F18","text":"The restricted stock units expire upon the earlier of the settlement of the units and the unitholder's termination of service."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":11300},"source":{"system":"sec-edgar","filing":"0000899243-18-007292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000089924318007292/doc4.xml","form_type":"4"}},{"id":3998387,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Stock Option (Right to buy)","published_at":"2018-03-13T18:01:16.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":75000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F15","text":"Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $450,750.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F14","text":"25% of the shares subject to the option vest on the first anniversary of the grant date of September 18, 2017, and the remainder vest monthly thereafter for 36 months."}],"balance_after":0,"derivative":{"exercise_price":3.99,"expiration_date":"2027-09-18","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-18-007292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000089924318007292/doc4.xml","form_type":"4"}},{"id":3998386,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Stock Option (Right to buy)","published_at":"2018-03-13T18:01:16.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":51200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F13","text":"Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $274,432.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"25% of the shares subject to the option vest on the first anniversary of the grant date of January 11, 2017, and the remainder vest monthly thereafter for 36 months."}],"balance_after":0,"derivative":{"exercise_price":4.64,"expiration_date":"2027-01-11","underlying":"Common Stock","underlying_shares":51200},"source":{"system":"sec-edgar","filing":"0000899243-18-007292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000089924318007292/doc4.xml","form_type":"4"}},{"id":3998385,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Stock Option (Right to buy)","published_at":"2018-03-13T18:01:16.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F11","text":"Pursuant to the Merger Agreement, the option was cancelled in exchange for a cash payment of $155,000.00, which represents the product of (a) the difference between $10.00 and the exercise price of the option per share, multiplied by (b) the number of shares subject to the option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"25% of the shares subject to the option vest on the first anniversary of the grant date of May 17, 2016, and the remainder vest monthly thereafter for 36 months."}],"balance_after":0,"derivative":{"exercise_price":6.9,"expiration_date":"2024-05-17","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-18-007292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000089924318007292/doc4.xml","form_type":"4"}},{"id":3998384,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Stock Option (Right to buy)","published_at":"2018-03-13T18:01:16.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":41667,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"25% of the shares subject to the option vest on the first anniversary of the grant date of September 24, 2015, and the remainder vest monthly thereafter for 36 months."}],"balance_after":0,"derivative":{"exercise_price":21.06,"expiration_date":"2023-09-24","underlying":"Common Stock","underlying_shares":41667},"source":{"system":"sec-edgar","filing":"0000899243-18-007292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000089924318007292/doc4.xml","form_type":"4"}},{"id":3998383,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Stock Option (Right to buy)","published_at":"2018-03-13T18:01:16.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":16667,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"25% of the shares subject to the option vest on the first anniversary of the grant date of December 16, 2014, and the remainder vest monthly thereafter for 36 months."}],"balance_after":0,"derivative":{"exercise_price":10.56,"expiration_date":"2022-12-16","underlying":"Common Stock","underlying_shares":16667},"source":{"system":"sec-edgar","filing":"0000899243-18-007292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000089924318007292/doc4.xml","form_type":"4"}},{"id":3998382,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Stock Option (Right to buy)","published_at":"2018-03-13T18:01:16.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":25000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"25% of the shares subject to the option vest on the first anniversary of the grant date of December 12, 2013, and the remainder vest monthly thereafter for 36 months."}],"balance_after":0,"derivative":{"exercise_price":10.44,"expiration_date":"2021-12-12","underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0000899243-18-007292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000089924318007292/doc4.xml","form_type":"4"}},{"id":3998381,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Stock Option (Right to buy)","published_at":"2018-03-13T18:01:16.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":8334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"25% of the shares subject to the option vest on the first anniversary of the grant date of December 12, 2012, and the remainder vest monthly thereafter for 36 months."}],"balance_after":0,"derivative":{"exercise_price":28.44,"expiration_date":"2020-12-12","underlying":"Common Stock","underlying_shares":8334},"source":{"system":"sec-edgar","filing":"0000899243-18-007292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000089924318007292/doc4.xml","form_type":"4"}},{"id":3998380,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Stock Option (Right to buy)","published_at":"2018-03-13T18:01:16.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":8334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"25% of the shares subject to the option vest on the first anniversary of the grant date of December 1, 2011, and the remainder vest monthly thereafter for 36 months."}],"balance_after":0,"derivative":{"exercise_price":41.52,"expiration_date":"2019-12-01","underlying":"Common Stock","underlying_shares":8.334},"source":{"system":"sec-edgar","filing":"0000899243-18-007292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000089924318007292/doc4.xml","form_type":"4"}},{"id":3998379,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Stock Option (Right to buy)","published_at":"2018-03-13T18:01:16.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":8334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"25% of the shares subject to the option vest on the first anniversary of the grant date of December 1, 2010, and the remainder vest monthly thereafter for 36 months."}],"balance_after":0,"derivative":{"exercise_price":19.92,"expiration_date":"2018-12-01","underlying":"Common Stock","underlying_shares":8334},"source":{"system":"sec-edgar","filing":"0000899243-18-007292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000089924318007292/doc4.xml","form_type":"4"}},{"id":3998378,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Stock Option (Right to buy)","published_at":"2018-03-13T18:01:16.000Z","date":"2018-03-09","kind":"disposition_to_issuer","acquired":false,"shares":6667,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, the option was cancelled and terminated without payment because the exercise price exceeded the Offer Price."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"25% of the shares subject to the option vest on the first anniversary of the grant date of November 10, 2010, and the remainder vest monthly thereafter for 36 months."}],"balance_after":0,"derivative":{"exercise_price":19.86,"expiration_date":"2018-11-10","underlying":"Common Stock","underlying_shares":6667},"source":{"system":"sec-edgar","filing":"0000899243-18-007292","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000089924318007292/doc4.xml","form_type":"4"}},{"id":3998377,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Common Stock","published_at":"2018-03-13T18:01:16.000Z","date":"2018-03-09","kind":"other","acquired":false,"shares":5237,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Shares of Common Stock tendered in the tender offer launched by Valley Acquisition Sub, Inc. on February 8, 2018 pursuant to that certain Agreement and Plan of Merger, dated January 30, 2018, among Seattle Genetics, Inc., Valley Acquisition Sub, Inc., and Cascadian Therapeutics, Inc. (the \"Merger Agreement\"), to acquire all of the outstanding shares of common stock of Cascadian Therapeutics, Inc., par value $0.0001 per share, at a purchase price of $10.00 per share (\"Offer Price\"), net to the seller in cash, without interest and less any required withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-18-007292","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000089924318007292/doc4.xml","form_type":"4"}},{"id":4079231,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Restricted Share Unit (RSU)","published_at":"2018-02-02T17:54:02.000Z","date":"2018-02-01","kind":"grant","acquired":true,"shares":199000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Approximately 70% of each RSU represents a contingent right to receive approximately 0.70 share of the issuer's Common Stock upon vesting and approximately 30% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent of the shares underlying the RSU vest on each of February 1, 2019, February 1, 2020, February 1, 2021 and February 1, 2022, subject to the holder's continued employment with the issuer on each vesting date."}],"balance_after":199000,"derivative":{"expiration_date":"2022-02-01","underlying":"Common Stock","underlying_shares":199000},"source":{"system":"sec-edgar","filing":"0001209191-18-007134","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919118007134/doc4.xml","form_type":"4"}},{"id":4099365,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Restricted Share Unit (RSU)","published_at":"2018-01-16T17:25:11.000Z","date":"2018-01-11","kind":"exercise","acquired":false,"shares":2825,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of the shares underlying the RSU vest on each of January 11, 2018, January 11, 2019, January 11, 2020 and January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date."}],"balance_after":8475,"derivative":{"expiration_date":"2027-01-11","underlying":"Common Stock","underlying_shares":2825},"source":{"system":"sec-edgar","filing":"0001209191-18-003645","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919118003645/doc4.xml","form_type":"4"}},{"id":4099364,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Common Stock","published_at":"2018-01-16T17:25:11.000Z","date":"2018-01-11","kind":"tax_withholding","acquired":false,"shares":923,"price":3.92,"value":3618.16,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"923 shares of the restricted share unit (\"RSU\") grant, which represent approximately 33% of the shares underlying the RSU grant that vested on January 11, 2018, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on January 11, 2018 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"923 shares of the restricted share unit (\"RSU\") grant, which represent approximately 33% of the shares underlying the RSU grant that vested on January 11, 2018, were not issued to the reporting holder; instead the reporting holder received an amount in cash from the issuer equal to the value of such shares based on the closing price of the issuer's Common Stock on January 11, 2018 to facilitate such holder's satisfaction of U.S. federal income tax obligations in connection with the vesting of the RSUs, which transaction does not represent a sale by the reporting person."}],"balance_after":5237,"source":{"system":"sec-edgar","filing":"0001209191-18-003645","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919118003645/doc4.xml","form_type":"4"}},{"id":4099363,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Common Stock","published_at":"2018-01-16T17:25:11.000Z","date":"2018-01-11","kind":"exercise","acquired":true,"shares":2825,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":6160,"source":{"system":"sec-edgar","filing":"0001209191-18-003645","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919118003645/doc4.xml","form_type":"4"}},{"id":4204839,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Restricted Share Unit (RSU)","published_at":"2017-09-20T21:10:55.000Z","date":"2017-09-18","kind":"grant","acquired":true,"shares":16500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of the shares underlying the RSU vest on each of September 18, 2018, September 18, 2019, September 18, 2020 and September 18, 2021, subject to the holder's continued employment with the issuer on each vesting date."}],"balance_after":16500,"derivative":{"expiration_date":"2021-09-18","underlying":"Common Stock","underlying_shares":16500},"source":{"system":"sec-edgar","filing":"0001209191-17-053537","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919117053537/doc4.xml","form_type":"4"}},{"id":4204838,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & CBO"}}],"security":"Stock Option (right to buy)","published_at":"2017-09-20T21:10:55.000Z","date":"2017-09-18","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and is exercisable at the rate of 1/4th of the total shares on September 18, 2018 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on September 18, 2021, subject to the holder's continued employment with the issuer on each vesting date."}],"balance_after":75000,"derivative":{"exercise_price":3.99,"expiration_date":"2027-09-18","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-17-053537","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919117053537/doc4.xml","form_type":"4"}},{"id":4491125,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & VP Corp. Dev."}}],"security":"Restricted Share Unit (RSU)","published_at":"2017-01-13T19:47:33.000Z","date":"2017-01-11","kind":"grant","acquired":true,"shares":11300,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Approximately 67% of each RSU represents a contingent right to receive approximately 0.67 share of the issuer's Common Stock upon vesting and approximately 33% represents a contingent right to receive cash upon vesting, which cash will be used to facilitate the holder's satisfaction of U.S. federal tax obligations in connection with the vesting of the RSUs."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent of the shares underlying the RSU vest on each of January 11, 2018, January 11, 2019, January 11, 2020 and January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date."}],"balance_after":11300,"derivative":{"expiration_date":"2021-01-11","underlying":"Common Stock","underlying_shares":11300},"source":{"system":"sec-edgar","filing":"0001209191-17-003756","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919117003756/doc4.xml","form_type":"4"}},{"id":4491124,"issuer":{"id":168341,"kind":"organization","name":"Cascadian Therapeutics, Inc.","symbol":"CASC"},"owners":[{"id":46440,"kind":"person","name":"EASTLAND JULIA MARIE","position":1,"cik":"0001500189","reported_name":"EASTLAND JULIA MARIE","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CFO & VP Corp. Dev."}}],"security":"Stock Option (right to buy)","published_at":"2017-01-13T19:47:33.000Z","date":"2017-01-11","kind":"grant","acquired":true,"shares":51200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests and is exercisable at the rate of 1/4th of the total shares on January 11, 2018 and then 1/48th of the total shares vest and are exercisable monthly thereafter, with 100% vested and exercisable on January 11, 2021, subject to the holder's continued employment with the issuer on each vesting date."}],"balance_after":51200,"derivative":{"exercise_price":4.64,"expiration_date":"2027-01-11","underlying":"Common Stock","underlying_shares":51200},"source":{"system":"sec-edgar","filing":"0001209191-17-003756","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1500189/000120919117003756/doc4.xml","form_type":"4"}}]}